Recombinant angioarrestin secreted from mouse melanoma cells inhibits growth of primary tumours

• Autorzy: Smagur A. , Szary J. , Szala S.
• Języki publikacji: EN

Abstrakty

EN

Angioarrestin is a recently described anti-angiogenic protein whose expression is down-regulated in solid tumours of various origins. It has a sequence identical to angiopoietin related protein-1. In this study we investigated anti-tumour properties of angioarrestin in B16 (F10) melanoma tumour model. We constructed an expression vector encoding human angioarrestin under the control of EF-1α promoter. This vector was transferred to B16 (F10) cells and recombinant angioarrestin secreted from the transfected cells was tested for anti-angiogenic activity using endothelial cell proliferation assay. Finally, mice were injected subcutaneously with cells that had been transfected with either angioarrestin-encoding vector or empty vector and tumor growth was compared. The obtained recombinant angioarrestin inhibited proliferation of bovine aortic endothelial cells. Tumours derived from an angioarrestin-secreting B16 (F10) cell clone grew in vivo more slowly than tumours derived from a cell clone transfected with empty vector. These data show, to our knowledge for the first time, that angioarrestin can inhibit primary melanoma tumour growth.

Słowa kluczowe

EN

anti-angiogenic protein; angioarrestin; anti-angiogenic factor; endothelial cell; angiopoietin; angiogenesis; tumour angiogenesis; tumour growth; growth factor; melanoma

• Wydawca: -
• Czasopismo: Acta Biochimica Polonica
• Rocznik: 2005
• Tom: 52
• Numer: 4
• Opis fizyczny: p.875-879,fig.,ref.

Twórcy

autor

Smagur A.

• Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Gliwice, Poland

autor

Szary J.

autor

Szala S.

Bibliografia

• Brown LF, Detmar M, Claffey K, Nagy JA, Feng D, Dvorak AM, Dvorak HF (1997) Vascular permeability factor/vascular endothelial growth factor: a multifunctional angiogenic cytokine. EXS 79: 233–269.
• Damert A, Ikeda E, Risau W (1997) Activator-protein-1 binding potentiates the hypoxia-inducible factor-1-mediated hypoxia-induced transcriptional activation of vascular-endothelial growth factor expression in C6 glioma cells. Biochem J 327: 419–423.
• Davis S, Aldrich TH, Jones PF, Acheson A, Compton DL, Jain V, Ryan TE, Bruno J, Radziejewski C, Maisonpierre PC, Yancopoulos GD (1996) Isolation of angiopoietin- 1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell 87: 1161–1169.
• Dhanabal M, LaRochelle WJ, Jeffers M, Herrmann J, Rastelli L, McDonald WF, Chillakuru RA, Yang M, Boldog FL, Padigaru M, McQueeney KD, Wu F, Minskoff SA, Shimkets RA, Lichenstein HS (2002) Angioarrestin: an antiangiogenic protein with tumor-inhibiting properties. Cancer Res 62: 3834–3841.
• Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD, Semenza GL (1996) Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 16: 4604–4613.
• Kim I, Moon SO, Koh KN, Kim H, Kwak HJ, Koh GY (1999) Molecular cloning, expression and characterization of angiopoietin-related protein. J Biol Chem 274: 26523–2658.
• Kim I, Kim HG, Kim H, Kim HH, Park SK, Uhm CS, Lee ZH, Koh GY (2000) Hepatic expression, synthesis and secretion of novel fibrinogen/angiopoietin-related protein prevents endothelial cell apoptosis. Biochem J 346: 603–610.
• Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ, Radziejewski C, Compton D, McClain J, Aldrich TH, Papadopoulos N, Daly TJ, Davis S, Sato TN, Yancopoulos GD (1997) Angiopoietin–2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 277: 55–60.
• Mizushima S, Nagata S (1990) pEF-BOS, a powerful mammalian expression vector. Nucleic Acids Res 18: 5322.
• Peek R, Kammerer RA, Frank S, Otte-Holler I, Westphal JR (2002) The angiopoietin-like factor cornea-derived transcript 6 is a putative morphogen for human cornea. J Biol Chem 277: 686–693.
• Procopio WN, Pelavin PI, Lee WM, Yeilding NM (1999) Angiopoietin-1 and -2 coiled coil domains mediate distinct homo-oligomerization patterns, but fibrinogenlike domains mediate ligand activity. J Biol Chem 274: 30196–30201.
• Rofstad EK, Danielsen T (1998) Hypoxia-induced angiogenesis and vascular endothelial growth factor secretion in human melanoma. Br J Cancer 77: 897–902.
• Salomon P, Kindler V, Ducrey O, Chapuis B, Zubler RH, Trono D (2000) High-level transgene expression in human hematopoietic progenitors and differentiated blood lineages after transduction with improved lentiviral vectors. Blood 96: 3392–3398.
• Suri C, Jones PF, Patan S, Bartunkova S, Maisonpierre PC, Davis S, Sato TN, Yancopoulos GD (1996) Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 87: 1171–1180.
• Szary J, Szala S (2001) Intratumoral administration of naked plasmid DNA encoding mouse endostatin inhibits renal tumor growth. Int J Cancer 91, 835–839.
• Valenzuela DM, Griffiths JA, Rojas J, Aldrich TH, Jones PF, Zhou H, McClain J, Copeland NG, Gilbert DJ, Jenkins NA, Huang T, Papadopoulos N, Maisonpierre PC, Davis S, Yancopoulos GD (1999) Angiopoietins 3 and 4: diverging gene counterparts in mice and humans. Proc Natl Acad Sci USA 96: 1904–1909.
• Wilczyńska U, Kucharska A, Szary J, Szala S (2001) Combined delivery of antiangiogenic protein (angiostatin) and immunomodulatory gene (interleukin-12) in the treatment of murine cancer. Acta Biochim Polon 48: 1077–10784.